Is semen analysis necessary prior to the commencement of testosterone supplementation therapy in men of reproductive age?

Authors

  • Michael Pan Baylor College of Medicine, Houston, Texas
  • Ranjith Ramasamy Baylor College of Medicine, Houston, Texas
  • Jason Ronald Kovac Urology of Indiana, 12188-A North Meridian Street Suite 200 Carmel, IN 46032

DOI:

https://doi.org/10.5489/cuaj.2259

Keywords:

testosterone supplementation therapy, hypogonadism, fertility preservation, semen analysis

Abstract

A semen analysis (SA) should be performed on all men of reproductive age prior to the commencement of testosterone supplementation therapy (TST).  A baseline SA has numerous benefits including the ability to unmask occult azoospermia, act as a baseline measure of reproductive function, and provide a recovery target for management of TST-induced testicular dysfunction.  Physicians treating men of reproductive age with TST should incorporate SA as part of their initial treatment protocol.

Downloads

Download data is not yet available.

Author Biographies

Michael Pan, Baylor College of Medicine, Houston, Texas

Medical Student

Ranjith Ramasamy, Baylor College of Medicine, Houston, Texas

Fellow in Reproductive Medicine and Surgery

Jason Ronald Kovac, Urology of Indiana, 12188-A North Meridian Street Suite 200 Carmel, IN 46032

Urologist, Indiana.

References

Basaria S. Male hypogonadism. Lancet 2014;383:1250-63.

Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice 2006;60:762-9.

Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS et al. Testosterone lab testing and initiation in the United kingdom and the United States, 2000 to 2011. The Journal of clinical endocrinology and metabolism 2014;99:835-42.

Smith RP, Khanna A, Coward RM, Rajanahally S, Kovac JR, Gonzales MA et al. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism. The journal of sexual medicine 2013;10:2326-33.

Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices. The journal of sexual medicine 2014;11:553-62.

Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone Supplementation Versus Clomiphene Citrate: An Age Matched Comparison Of Satisfaction And Efficacy. The Journal of urology 2014.

de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU international 2011;108:1860-5.

Moss JL, Crosnoe LE, Kim ED. Effect of rejuvenation hormones on spermatogenesis. Fertility and sterility 2013;99:1814-20.

Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. The Journal of urology 2013;190:2200-5.

Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. The Journal of clinical endocrinology and metabolism 2009;94:1910-5.

. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990;336:955-9.

Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and sterility 2014;101:1271-9.

Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. The Journal of urology 2013;189:647-50.

Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. The Journal of clinical endocrinology and metabolism 2005;90:2595-602.

Downloads

Published

2014-12-15

How to Cite

Pan, M., Ramasamy, R., & Kovac, J. R. (2014). Is semen analysis necessary prior to the commencement of testosterone supplementation therapy in men of reproductive age?. Canadian Urological Association Journal, 8(11-12), 446–7. https://doi.org/10.5489/cuaj.2259

Issue

Vol. 8 No. 11-12 (2014): CUAJ December

Section

Opinion

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.